Balance Sheet
Cash Flow Statement
Gains from Investment SecuritiesGains from Sales and DivestituresOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Gains from Investment Securities (2020 - 2025)

IceCure Medical (ICCM) has disclosed Gains from Investment Securities for 3 consecutive years, with $3.1 million as the latest value for Q4 2022.

  • On a quarterly basis, Gains from Investment Securities rose 12386.04% to $3.1 million in Q4 2022 year-over-year; TTM through Dec 2022 was $3.1 million, a 12386.04% increase, with the full-year FY2024 number at $116000.0, down 39.9% from a year prior.
  • Gains from Investment Securities was $3.1 million for Q4 2022 at IceCure Medical, up from $24635.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.1 million in Q4 2022 to a low of $24635.0 in Q4 2021.
  • A 3-year average of $1.5 million and a median of $1.5 million in 2020 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 98.31% in 2021, then skyrocketed 12386.04% in 2022.
  • IceCure Medical's Gains from Investment Securities stood at $1.5 million in 2020, then plummeted by 98.31% to $24635.0 in 2021, then surged by 12386.04% to $3.1 million in 2022.
  • Per Business Quant, the three most recent readings for ICCM's Gains from Investment Securities are $3.1 million (Q4 2022), $24635.0 (Q4 2021), and $1.5 million (Q4 2020).